Pharmaceutical company Johnson & Johnson (JNJ) has reported strong financial results for the fourth quarter of 2025.
The New Jersey-based company announced earnings per share of $2.46 U.S., which was ahead of the $2.42 U.S. forecast on Wall Street.
Revenue in the period totaled $24.56 billion U.S., beating consensus expectations of $24.10 billion U.S. Sales rose 9.1% from a year earlier.
Despite the top and bottom-line beats, JNJ stock is down 2% after the latest results were announced.
The stock is falling on weak sales of the drug Stelara, which has long been one of Johnson & Johnson’s biggest sellers.
Johnson & Johnson lost patent protection on Stelara last year. As a result, sales of the medication fell 48% year-over-year in the final quarter of 2025.
Stelara is used to treat autoimmune diseases such as psoriasis, arthritis, Crohn's disease, and ulcerative colitis.
Even with the Stelara setback, management at Johnson & Johnson managed to issue strong guidance for 2026.
The company said that it expects full-year earnings of $11.53 U.S. a share on sales of $100.5 billion U.S. That’s ahead of the $11.48 U.S. in per share profits and sales of $98.9 billion U.S. forecast by analysts.
Prior to today (Jan. 21), JNJ stock had risen 47% over the last 12 months to trade at $218.21 U.S. per share.
